754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)

Autor:	Haven Garber, Saranya Chumsri, Yazan Migdady, Chul Kim, Erika Hamilton, Jennifer Specht, Babar Bashir, Hirva Mamdani, Heidi Gillenwater, Yeonhee Kim, David R Spigel, Usama Gergis, Hemant S Murthy, Lubna N Chaudhary, Sarah Fitzsimmons, Bishwa J Ganguly, Hajime Hiraragi, Helle Jensen, Mary C Lessig
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Druh dokumentu:	article
ISSN:	2051-1426
DOI:	10.1136/jitc-2023-SITC2023.0754
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/22595beb19204c3fae68bc30f71d834e Zobrazit plný text záznamu View record in DOAJ